Seres Therapeutics Inc【MCRB】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live...

Form 8-K - Current report

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential...

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related...

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and...

REAGAN 7月前

I sold at $27.42. I bought at $8.64. This company is an effing scam. No product. No employees and zero possibility for f creating revenue any time. I knew it was being shorted and the dilution machine had stopped. It's worthless shell with $40m in cash. This will be bankrupt this time next year. The nestle deal is a joke. The previous ceo is a Cvnt for not selling at $6.00 a share. Glad I made serious bank. $23k profit.

👍️0

REAGAN 10月前

Short data out from FINRA says 16.4% sold short. They sold a 100k short today. This will break out tomorrow above $22 and be over $35 by end of next week if we get whales to come in

👍️0

Cosa 1年前

They have $58M left...

👍️0

Cosa 1年前

RS to get ready to start diluting shareholders again....? Curious to see how much cash they have left on next ER.

👍️0

ConnorMic 1年前

Jean fm got any contacts at nestle that could give u vowst sales ?

👍️0

glenn1919 1年前

MCRB.......................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2年前

MCRB...............................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

Appears to be a good biotech

👍️0

FrostyStar1 2年前

The are looking for a partner which would share in burn. You seem to be clueless.

👍️0

FrostyStar1 2年前

He ran away cause he was wrong. He was a pumper.

Carmen for the win 2年前

Dear Mon Ami JeanFM, I hope all is well. Do you have any news from Switzerland?

👍️0

Cosa 2年前

Acquisition offer? Old news..we heard it first from JeanFM lol.

👍️0

glenn1919 2年前

MCRB......................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

👍️0

Cosa 2年前

Holding nothing. This management is Terrible. They will need to raise funds within 8 months further diluting shareholders. They burn nearly $40 million a quarter. The money they're getting from the sale will not last long. SER-155 will be a specialty drug which equals little revenue if it even makes it that far. This is just my opinion and I have been wrong many times. Good luck if you are holding.

👍️0

Cosa 2年前

Reduced position to 15% of original holding. Average profit of 40%, taking the win. Management makes this company risky!

👍️0

Cosa 2年前

Exited another 10% of position. Taking some off the table just in case...

👍️0

Cosa 2年前

Bought the dip at $1.10 the other day and sold that today and %5 more of my core position. Will start another position if it dips again.

👍️0

glenn1919 2年前

MCRB...........................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

Feel Great about the $2.00 calls I bought yesterday.
Close over 1.50 next!

$MCRB

👍️0

TechandBio 2年前

was buying Seres for .77 a month ago. I'm holding for $2.00+ same for $ICCM expect a similar move soon.

$MCRB

👍️0

Cosa 2年前

The past few days have been great! Sold off 15% of my position today. Taking some off the table for profits.

👍️0

glenn1919 2年前

MCRB.....................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

👍️0

TechandBio 2年前

Just sold my MCRB for a double. Looking for a 10x in ICCM Cure early breast cancer 97% after multiple 5 year independent data studies and late stage breast cancer data with large tumors 93%
$MCRB

👍️0

RiddleGuru99 2年前

Jeanfm. Any update on this or is it basically dead?

👍️0

ConnorMic 2年前

are u still there Jean fm

👍️0

ConnorMic 2年前

He has loads of rsu’s at 3 bucks and 5 bucks. He would come out swimming if they sold the whole company. To me he is flagships guy though so he’ll do whatever they tell him and seems like flagship wants to keep things moving as a clinical stage company. See-155 is phase 1. No way nestle partners and gives them upfront cash at this point. They might sell the rest of the portfolio to someone else or partner with someone. As it stands today this would go from a pharma with revenue and a commercialized product to a very early stage bio and it’s hard to imagine long term institutional investors are over the moon about this. So if it stays as is can’t believe they have the vote and stock price is giving them that signal. Lots of time for them to change the deal.

👍️0

Cosa 2年前

Selling the company is out for one simply reason. Management doesn't hold too much shares. For instance CEO Eric Shaff's salary in 2023 was estimated to be about $685k with other compensation totaling over $3m. According to my etrade account Eric holds 140,698 shares on 5/15/2024. If Nestle offered $5.20 a share, that make his shares worth $731,629. I'm not sure how many more options or RSU's would vest which would increase this number. But $700k is an easy "No" for him as he would be out of a job and makes more keeping it. This is all my opinion and for entertainment purposes.

https://finance.yahoo.com/news/increases-seres-therapeutics-inc-nasdaq-164726562.html

👍️0

Cosa 2年前

If they do sell VOWST and strike a deal for SER-155, that would be more bullish.

This is from SER-109 article in 2021 but changed it to SER-155 for entertainment purposes.
Under the terms of the agreement, Nestlé Health Science will utilize its global pharmaceutical business Aimmune Therapeutics and will assume the role of lead commercialization party. Seres will receive license payments of $175 million up front, and an additional $125 million upon FDA approval of SER-155. The agreement also includes sales target milestones which, if achieved, could total up to $225 million. Seres will be responsible for development and pre-commercialization costs in the U.S. Upon commercialization, Seres will be entitled to an amount equal to 50% of the commercial profits.

Original Article:
https://www.businesswire.com/news/home/20210701005405/en/Seres-Therapeutics-Nestl%C3%A9-Health-Science-Announce-SER-109-Co-Commercialization-License-Agreement

👍️0

Cosa 2年前

Not sure if shareholders would vote in favor of $230M. Maybe up to $300M

If you read this from the article below. And based on their last ER. They have about $102M in liabilities. They have cash of about $125M, which is expected to be runway to Q4 2024.

With capital expected from transaction they will pay off $102M and have a cash runway to Q4 2025. They are going to sell the remaining 50% rights for about $230M. This would pay off debt and leave them with $250M cash runway. Assuming that $125M was our runway to Q4 this year and another $125M is for the year 2025. Probably have a milestone payment in there also.

Clip from article below.
Seres expects to use the capital from this transaction to fully retire its senior secured debt facility with Oaktree Capital Management, and support the further advancement of SER-155 and its other cultivated microbiome product candidates. Based on Seres' current cash, its future operating plans, and the capital expected to be obtained from the transaction, the Company anticipates being able to extend its cash runway into Q4 2025, subject to performance under the transition services agreement.
Source:
https://ih.advfn.com/stock-market/NASDAQ/seres-therapeutics-MCRB/stock-news/93996839/seres-therapeutics-enters-into-memorandum-of-under

All just made up numbers for entertainment purposes.

👍️0

ConnorMic 2年前

Comment v’as Tu Jean. As Tu encore des connection chez nestle? As tu des nouvelles?

👍️0

ConnorMic 2年前

At the time maybe that was total shares outstanding ? Maybe minus the ones nestle already owns.

Tomorrow $0.75 needs to hold

👍️0

Carmen for the win 2年前

Dear Jean, thank you for the info you have shared. In one of your previous posts you wrote "119000000 À 5.20" what did you mean by that?

👍️0

Cosa 2年前

I'm no longer doubting that you knew something. Just didn't work in the way it was originally planned. Thanks Jean

👍️0

ConnorMic 2年前

Ok merci Jean. Pense-Tu que seres a du non valeur apres ca ?

👍️0

JeanFM 2年前

J'AI VU LE PROJET CHEZ VEVE L'OFFRE ÉTAIT 5,20 $ POUR CHAQUE ACTION DE SERES CLASSE A

Nestlé S.A voulait que l'entreprise et les actionnaires soient payés. Blâmez la direction et non Nestlé S.A ici à Veve

👍️0

JeanFM 2年前

L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024

👍️0

JeanFM 2年前

L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024

👍️0

JeanFM 2年前

L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024

👍️0

Cosa 2年前

If that is the case, Seres shareholders would be absolutely angered. EGM and fire everyone. But we won't know unless Nestle goes public with the offer. Which I doubt they will, because if they ink this deal in would be a win win for them. They would have full rights to VOWST and not have to take on Seres debt.

👍️ 1

JeanFM 2年前

l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune

Thank you for your input! Could you please elaborate on what you said regarding the news for next week. Apparently, the market hates today's announcement.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Seres Therapeutics Inc (MCRB)

個人投資家向けのプロ仕様のツール。

Seres Therapeutics Inc (MCRB) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Form 8-K - Current report

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

MCRB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Seres Therapeutics Inc (MCRB)

個人投資家向けのプロ仕様のツール。

Seres Therapeutics Inc (MCRB) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Form 8-K - Current report

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

MCRB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する